A group of researchers at the Guangdong Academy of Medical Sciences in Guangzhou, China have retracted a paper that came out of a clinical trial on transarterial chemoembolization, a targeted kind of chemotherapy.
According to the notice, one of the authors mixed up the control samples with the clinical samples, and “could not recall which samples were in the wrong group.” The paper hasn’t yet been cited, according to Thomson Scientific’s Web of Knowledge.
Here’s the notice in Medical Oncology:
Article “Clinical value of circulating tumor cells for the prognosis of postoperative transarterial chemoembolization therapy” by Jian-wen Huang, Bing Liu, Bao-shan Hu, Yong Li, Xu He, Wei Zhao, You-bing Zheng, Li-gong Lu, published in Volume 31, Issue 9, DOI: 10.1007/s12032-014-0175-5 has been retracted at the request of the authors. The author who was responsible for circulating tumor cells counting mistook some TACE group samples for control group samples in collecting and could not recall which samples were in the wrong group.
The authors apologize for any inconvenience this might have caused.
We emailed the authors and the editor, and will update with any new information.
Hat tip: Rolf Degen